Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
06:21pm, Thursday, 07'th Nov 2024
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 07'th Nov 2024
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 milli
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
09:05am, Tuesday, 05'th Nov 2024
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS - Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUT
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
08:05am, Thursday, 31'st Oct 2024
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
04:35pm, Thursday, 24'th Oct 2024
SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer,
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
10:00am, Wednesday, 16'th Oct 2024
ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, I
Rigel Pharmaceuticals: Looking For More Growth
07:32am, Thursday, 10'th Oct 2024
Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical n
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
08:42pm, Wednesday, 09'th Oct 2024
Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavali
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 04'th Oct 2024
SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
05:35am, Wednesday, 25'th Sep 2024
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel to Present at the 2024 Cantor Global Healthcare Conference
08:05am, Thursday, 12'th Sep 2024
SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today an
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
07:30am, Thursday, 05'th Sep 2024
First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patie
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
08:00am, Tuesday, 03'rd Sep 2024
Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea and Taiwan Rigel will receive an upfront cash paymen
Rigel to Participate in Upcoming September Investor Conferences
08:05am, Thursday, 29'th Aug 2024
SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ann
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript
02:12pm, Friday, 09'th Aug 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary Raul Rodriguez - Pre
